Galecto

GLTO

Market cap $40M

24.98 USD

+1.03

4.3%

At close Updated Jan 16, 4:00 PM EST

Pre-market

After hours

24.97

-0.01

0.04%

1 day

4.3%

5 days

23.6%

1 month

-16.73%

3 months

127.3%

6 months

613.71%

Year to date

14.48%

1 year

439.52%

5 years

-92.22%

10 years

-93.34%

About: Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.

Employees: 5

Healthcare Biotechnology